Knowledge and Acceptance of the COVID-19 Vaccine for COVID-19 Disease Prevention among the Indian Population: A Mixed-Method Study
Abstract
:1. Introduction
2. Materials and Methods
2.1. Sampling and Recruitment
2.2. Quantitative Phase
2.3. Qualitative Phase
2.4. Interview Procedure
2.5. Data Management and Analysis
3. Results
3.1. Age Group Wise Distribution of Study Participants Based on Their Knowledge Regarding COVID-19 Disease
3.2. Gender Wise Distribution of Study Participants Based on Their Knowledge Regarding COVID-19 Disease
3.3. Age Group Wise Distribution of Study Participants Based on Their Acceptance for COVID-19 Vaccine
3.4. Gender Wise Distribution of Study Participants Based on Their Acceptance for COVID-19 Vaccine
3.5. Overall Knowledge
3.6. Qualitative Phase
3.7. Knowledge of COVID-19 and Its Transmission
- Prevention
- Acceptance assessment of COVID-19 vaccine
- No acceptance (safety concern)
- Complete acceptance
- Barriers
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Chakraborty, I.; Maity, P. COVID-19 outbreak: Migration, effects on society, global environment and prevention. Sci. Total Environ. 2020, 728, 138882. [Google Scholar] [CrossRef] [PubMed]
- Suresh, R.; James, J.; RSj, B. Migrant Workers at Crossroads–The COVID-19 Pandemic and the Migrant Experience in India. Soc. Work. Public Health 2020, 35, 633–643. [Google Scholar] [CrossRef] [PubMed]
- Rolland, J.S. COVID-19 pandemic: Applying a multisystemic lens. Fam. Process 2020, 59, 922–936. [Google Scholar] [CrossRef] [PubMed]
- Azlan, A.A.; Hamzah, M.R.; Sern, T.J.; Ayub, S.H.; Mohamad, E. Public knowledge, attitudes and practices towards COVID-19: A cross-sectional study in Malaysia. PLoS ONE 2020, 15, e0233668. [Google Scholar] [CrossRef]
- Ferrara, E. # COVID-19 on twitter: Bots, conspiracies, and social media activism. arXiv 2020, arXiv:2004.09531. [Google Scholar]
- Rodrigues, C.; Plotkin, S.A. Impact of vaccines; health, economic and social perspectives. Front. Microbiol. 2020, 11, 1526. [Google Scholar] [CrossRef]
- Ferdous, M.Z.; Islam, M.S.; Sikder, M.T.; Mosaddek, A.S.; Zegarra-Valdivia, J.A.; Gozal, D. Knowledge, attitude, and practice regarding COVID-19 outbreak in Bangladesh: An online-based cross-sectional study. PLoS ONE 2020, 15, e0239254. [Google Scholar] [CrossRef] [PubMed]
- Machingaidze, S.; Wiysonge, C.S. Understanding COVID-19 vaccine hesitancy. Nat. Med. 2021, 27, 1338–1339. [Google Scholar] [CrossRef]
- Vannabouathong, C.; Devji, T.; Ekhtiari, S.; Chang, Y.; Phillips, S.A.; Zhu, M.; Chagla, Z.; Main, C.; Bhandari, M. Novel coronavirus COVID-19: Current evidence and evolving strategies. J. Bone Jt. Surg. Am. 2020, 102, 734. [Google Scholar] [CrossRef]
- He, X.; Hong, W.; Pan, X.; Lu, G.; Wei, X. SARS-CoV-2 Omicron variant: Characteristics and prevention. MedComm 2021, 2, 838–845. [Google Scholar] [CrossRef]
- Torjesen, I. COVID-19: Omicron may be more transmissible than other variants and partly resistant to existing vaccines, scientists fear. BMJ 2021, 375, n2943. [Google Scholar] [CrossRef] [PubMed]
- Maxmen, A. How blood from COVID-19 survivors might save lives. Nature 2020, 580, 16–18. [Google Scholar] [CrossRef] [PubMed]
- Kiyuka, P.K.; Moindi, R.O.; Murunga, N.; Muinga, N.; Mutua, M.N.; Wanjala, S.; Sandra, S.; Mumba, N.; Odhiambo, E.O.; Mutengu, L.; et al. Assessing risk perceptions that contribute to tetanus toxoid maternal vaccine hesitancy in Kilifi County, Kenya. medRxiv 2021. [Google Scholar] [CrossRef]
- Silvers, L.E.; Ellenberg, S.S.; Wise, R.P.; Varricchio, F.E.; Mootrey, G.T.; Salive, M.E. The epidemiology of fatalities reported to the Vaccine Adverse Event Reporting System 1990–1997. Pharmacoepidemiol. Drug Saf. 2001, 10, 279–285. [Google Scholar] [CrossRef] [PubMed]
- Passarelli-Araujo, H.; Pott-Junior, H.; Susuki, A.M.; Olak, A.S.; Pescim, R.R.; Tomimatsu, M.F.A.I.; Volce, C.J.; Neves, M.A.Z.; Silva, F.F.; Narciso, S.G.; et al. The impact of COVID-19 vaccination on case fatality rates in a city in Southern Brazil. Am. J. Infect. Control 2022, 50, 491–496. [Google Scholar] [CrossRef] [PubMed]
- Verma, A.; Prakash, S. Impact of COVID-19 on environment and society. J. Glob. Biosci. 2020, 9, 7352–7363. [Google Scholar]
- Dhama, K.; Sharun, K.; Tiwari, R.; Dhawan, M.; Emran, T.B.; Rabaan, A.A.; Alhumaid, S. COVID-19 vaccine hesitancy–reasons and solutions to achieve a successful global vaccination campaign to tackle the ongoing pandemic. Hum. Vaccines Immunother. 2021, 17, 3495–3499. [Google Scholar] [CrossRef]
- Cordina, M.; Lauri, M.A. Attitudes towards COVID-19 vaccination, vaccine hesitancy and intention to take the vaccine. Pharm. Pract. Granada 2021, 19. [Google Scholar] [CrossRef]
- Wong, L.P.; Alias, H.; Wong, P.F.; Lee, H.Y.; AbuBakar, S. The use of the health belief model to assess predictors of intent to receive the COVID-19 vaccine and willingness to pay. Hum. Vaccines Immunother. 2020, 16, 2204–2214. [Google Scholar] [CrossRef]
- Murphy, J.; Vallières, F.; Bentall, R.P.; Shevlin, M.; McBride, O.; Hartman, T.K.; McKay, R.; Bennett, K.; Mason, L.; Gibson-Miller, J.; et al. Psychological characteristics associated with COVID-19 vaccine hesitancy and resistance in Ireland and the United Kingdom. Nat. Commun. 2021, 12, 29. [Google Scholar] [CrossRef]
- Khubchandani, J.; Saiki, D.; Kandiah, J. Masks, gloves, and the COVID-19 pandemic: Rapid assessment of public behaviours in the United States. Epidemiologia 2020, 1, 16–22. [Google Scholar] [CrossRef]
- Fisher, K.A.; Bloomstone, S.J.; Walder, J.; Crawford, S.; Fouayzi, H.; Mazor, K.M. Attitudes Toward a Potential SARS-CoV-2 Vaccine: A Survey of, U.S. Adults. Ann. Intern. Med. 2020, 173, 964–973. [Google Scholar] [CrossRef] [PubMed]
- Szilagyi, P.G.; Thomas, K.; Shah, M.D.; Vizueta, N.; Cui, Y.; Vangala, S.; Kapteyn, A. National Trends in the US Public’s Likelihood of Getting a COVID-19 Vaccine April 1 to December 8, 2020. JAMA 2020, 325, 396–398. [Google Scholar] [CrossRef] [PubMed]
- Marya, A.; Venugopal, A.; Karobari, M.I.; Messina, P.; Scardina, G.A.; Subramanian, A.K. The Exponential Rise of Teledentistry and Patient-Oriented Protective Measures in Southeast Asian Dental Clinics: Concerns, Benefits, and Challenges. Int. J. Dent. 2021, 2021, 9963329. [Google Scholar] [CrossRef]
- Marya, A.; Karobari, M.I.; Selvaraj, S.; Adil, A.H.; Assiry, A.A.; Rabaan, A.A.; Horn, R.; Venugopal, A.; Messina, P.; Scardina, G.A. Risk perception of SARS-CoV-2 infection and implementation of various protective measures by dentists across various countries. Int. J. Environ. Res. Public Health 2021, 18, 5848. [Google Scholar] [CrossRef]
- Karobari, M.I.; Marya, A.; Venugopal, A.; Nalabothu, P.; Parveen, A.; Noorani, T.Y. The state of orthodontic practice after the outbreak of COVID-19 in Southeast Asia: The current scenario and future recommendations. Asia Pac. J. Public Health 2020, 32, 517–518. [Google Scholar] [CrossRef]
Knowledge (n = 606) | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Age Groups | Heard about COVID-19 | Source of Knowledge (News) | Infected with COVID-19 | Know the Causes of COVID-19 (Virus) | How Person Can Get COVID-19 (Direct Contact with Infected Person, Touching Infected Surface and Eating Contaminate Food) | Knows the Measures to Prevent COVID-19 | Preferable Vaccine for COVID-19 (Covishield) | Total | |||||||
n | % | n | % | n | % | n | % | n | % | n | % | n | % | ||
16–25 years | 166 | 97.6% | 166 | 97.6% | 46 | 27.1% | 164 | 96.5% | 42 | 24.7% | 162 | 95.3% | 88 | 51.8% | 170 |
26–40 years | 224 | 99.1% | 208 | 92.0% | 82 | 36.3% | 202 | 89.4% | 96 | 42.5% | 196 | 86.7% | 126 | 57.1% | 226 |
41–60 years | 162 | 100.0% | 147 | 90.7% | 62 | 38.38.3% | 124 | 76.5% | 62 | 38.3% | 132 | 81.5% | 84 | 51.9% | 162 |
>60 years | 48 | 100.0% | 34 | 70.8% | 8 | 16.7% | 26 | 54.2% | 22 | 45.8% | 34 | 70.8% | 16 | 33.3% | 48 |
Gender | Heard about COVID-19 | Source of Knowledge (News) | Infected with COVID-19 | Know the Causes of COVID-19 (Virus) | How Person Can Get COVID-19 (Direct Contact with Infected Person, Touching Infected Surface and Eating Contaminate Food) | Knows the Measures to Prevent COVID-19 | Preferable Vaccine for COVID-19 (Covishield) | Total | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
n | % | n | % | n | % | n | % | n | % | n | % | n | % | ||
Female | 276 | 98.6% | 252 | 90.0% | 78 | 27.9% | 236 | 84.3% | 104 | 37.1% | 242 | 86.4% | 152 | 54.3% | 170 |
Male | 324 | 99.4% | 303 | 92.9% | 120 | 36.8% | 280 | 85.9% | 118 | 36.2% | 282 | 86.5% | 165 | 50.6% | 226 |
p value | 0.422 | 0.268 | 0.024 | 0.607 | 0.203 | 0.931 | 0.186 |
Age Groups | Are You Vaccinated | In Future Which Vaccine You Would Prefer to Get Vaccinate (Covishield) | Even after Getting Vaccination, You Still Have Chances to Get COVID Disease | Know about the Side Effects of COVID-19 Vaccine (Fever, Headache, Pain, Swelling, Fatigue) | Are You Afraid All Because of Side Effects of COVID Vaccine | Any Comorbidity Stopping You from Getting COVID Vaccine (Diabetes) | Recommend COVID-19 Vaccine to Others | Do You Think COVID-19 Vaccine Is Safe in Pregnant and Lactating Women | Do You Think COVID-19 Vaccine Is Safe in Children below 18 Years | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | |
16–25 years | 152 | 89.4% | 86 | 50.6% | 162 | 95.3% | 25 | 14.7% | 80 | 47.1% | 0 | 0% | 168 | 98.8% | 120 | 70.6% | 84 | 49.4% |
26–40 years | 190 | 84.1% | 118 | 52.2% | 218 | 96.5% | 21 | 9.3% | 136 | 60.2% | 0 | 0% | 218 | 96.5% | 144 | 63.7% | 106 | 46.9% |
41–60 years | 132 | 81.5% | 66 | 40.7% | 140 | 86.4% | 20 | 12.3% | 126 | 77.8% | 4 | 2.5% | 144 | 88.9% | 106 | 65.4% | 70 | 43.2% |
>60 years | 26 | 54.2% | 18 | 37.5% | 34 | 70.8% | 8 | 16.7% | 32 | 66.7% | 2 | 4.2% | 26 | 54.2% | 20 | 41.7% | 18 | 37.5% |
Gender | Are You Vaccinated | In Future Which Vaccine You Would Prefer to Get Vaccinate (Covishield) | Even after Getting Vaccination, You Still Have Chances to Get COVID Disease | Are You Afraid All Because of Side Effects of COVID Vaccine | Any Comorbidity Stopping You from Getting COVID Vaccine (Diabetes) | Recommend COVID-19 Vaccine to Others | Do You Think COVID-19 Vaccine Is Safe in Pregnant and Lactating Women | Do You Think COVID-19 Vaccine Is Safe in Children below 18 Years | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | |
Female | 228 | 81.4% | 127 | 45.4% | 248 | 88.6% | 162 | 57.9% | 6 | 2.1% | 258 | 92.1% | 168 | 60.0% | 128 | 45.7% |
Male | 272 | 83.4% | 161 | 49.4% | 306 | 93.9% | 212 | 65.0% | 0 | 0.0% | 298 | 91.7% | 222 | 68.1% | 150 | 46.0% |
p value | 0.522 | 0.291 | 0.028 | 0.078 | 0.010 | 0.769 | 0.041 | 1.000 |
Ouestions Asked: | n | % |
---|---|---|
1 Have you ever heard about COVID-19 disease | 600 | 99.0% |
2 From where did you hear about COVID-19 disease (news) | 555 | 91.6% |
3 Have you ever been infected with the COVID disease | 198 | 32.7% |
4 According to you what are the cause of COVID-19 disease (virus) | 516 | 85.1% |
5 Do you know how a person can get COVID-19 disease (Direct contact with infected person, touching infected surface and eating contaminate food) | 222 | 36.2% |
6 Do you know the measures to prevent COVID-19 disease | 524 | 86.5% |
7 According to you which vaccine is best for prevention of COVID-19 (Covishield) | 317 | 52.3% |
Ouestions Asked: | n | % |
---|---|---|
Are you vaccinated | 500 | 82.5% |
In future which vaccine you would prefer to get vaccinate (covishield) | 288 | 47.5% |
Even after getting vaccination, you still have chances to get COVID disease | 554 | 91.4% |
Know about the side effects of COVID-19 vaccine (fever, headache, pain, swelling, fatigue) | 74 | 12.2% |
Are you afraid all because of side effects of COVID vaccine | 374 | 61.7% |
Any comorbidity stopping you from getting COVID vaccine (diabetes) | 6 | 1.0% |
Recommend COVID-19 vaccine to others | 556 | 91.7% |
Do you think COVID-19 vaccine is safe in pregnant and lactating women | 390 | 64.4% |
Do you think COVID-19 vaccine is safe in children below 18 years | 278 | 45.9% |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Taneja, P.; Marya, C.M.; Kashyap, P.; Kataria, S.; Nagpal, R.; Karobari, M.I.; Marya, A. Knowledge and Acceptance of the COVID-19 Vaccine for COVID-19 Disease Prevention among the Indian Population: A Mixed-Method Study. Vaccines 2022, 10, 1605. https://doi.org/10.3390/vaccines10101605
Taneja P, Marya CM, Kashyap P, Kataria S, Nagpal R, Karobari MI, Marya A. Knowledge and Acceptance of the COVID-19 Vaccine for COVID-19 Disease Prevention among the Indian Population: A Mixed-Method Study. Vaccines. 2022; 10(10):1605. https://doi.org/10.3390/vaccines10101605
Chicago/Turabian StyleTaneja, Pratibha, Charu Mohan Marya, Parul Kashyap, Sakshi Kataria, Ruchi Nagpal, Mohmed Isaqali Karobari, and Anand Marya. 2022. "Knowledge and Acceptance of the COVID-19 Vaccine for COVID-19 Disease Prevention among the Indian Population: A Mixed-Method Study" Vaccines 10, no. 10: 1605. https://doi.org/10.3390/vaccines10101605
APA StyleTaneja, P., Marya, C. M., Kashyap, P., Kataria, S., Nagpal, R., Karobari, M. I., & Marya, A. (2022). Knowledge and Acceptance of the COVID-19 Vaccine for COVID-19 Disease Prevention among the Indian Population: A Mixed-Method Study. Vaccines, 10(10), 1605. https://doi.org/10.3390/vaccines10101605